LAMEA Filgrastim Market Size & Share Forecast 2021-2027

LAMEA Filgrastim Market By Drug Type (Biosimilar and Biologic), By Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

Published Date: December-2021 | Number of Pages: 82 | Format: PDF | Report ID: KBV-16053

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Filgrastim Market, by Drug Type
1.4.2 LAMEA Filgrastim Market, by Indication
1.4.3 LAMEA Filgrastim Market, by Distribution Channel
1.4.4 LAMEA Filgrastim Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. LAMEA Filgrastim Market by Drug Type
3.1 LAMEA Biosimilar Market by Country
3.2 LAMEA Biologic Market by Country

Chapter 4. LAMEA Filgrastim Market by Indication
4.1 LAMEA Chemotherapy induced Neutropenia Market by Country
4.2 LAMEA Chronic Neutropenia Market by Country
4.3 LAMEA Other Indications Market by Country

Chapter 5. LAMEA Filgrastim Market by Distribution Channel
5.1 LAMEA Hospital Pharmacies Market by Country
5.2 LAMEA Retail Pharmacies Market by Country
5.3 LAMEA Online Pharmacies Market by Country

Chapter 6. LAMEA Filgrastim Market by Country
6.1 Brazil Filgrastim Market
6.1.1 Brazil Filgrastim Market by Drug Type
6.1.2 Brazil Filgrastim Market by Indication
6.1.3 Brazil Filgrastim Market by Distribution Channel
6.2 Argentina Filgrastim Market
6.2.1 Argentina Filgrastim Market by Drug Type
6.2.2 Argentina Filgrastim Market by Indication
6.2.3 Argentina Filgrastim Market by Distribution Channel
6.3 UAE Filgrastim Market
6.3.1 UAE Filgrastim Market by Drug Type
6.3.2 UAE Filgrastim Market by Indication
6.3.3 UAE Filgrastim Market by Distribution Channel
6.4 Saudi Arabia Filgrastim Market
6.4.1 Saudi Arabia Filgrastim Market by Drug Type
6.4.2 Saudi Arabia Filgrastim Market by Indication
6.4.3 Saudi Arabia Filgrastim Market by Distribution Channel
6.5 South Africa Filgrastim Market
6.5.1 South Africa Filgrastim Market by Drug Type
6.5.2 South Africa Filgrastim Market by Indication
6.5.3 South Africa Filgrastim Market by Distribution Channel
6.6 Nigeria Filgrastim Market
6.6.1 Nigeria Filgrastim Market by Drug Type
6.6.2 Nigeria Filgrastim Market by Indication
6.6.3 Nigeria Filgrastim Market by Distribution Channel
6.7 Rest of LAMEA Filgrastim Market
6.7.1 Rest of LAMEA Filgrastim Market by Drug Type
6.7.2 Rest of LAMEA Filgrastim Market by Indication
6.7.3 Rest of LAMEA Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Amgen, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Novartis AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy’s Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Apotex, Inc.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Product Launches and Product Expansions:
7.10 Toksöz Group
7.10.1 Company Overview

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities